Neither the Securities and Exchange Commission (the “SEC”)
nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this
pricing supplement or the accompanying product supplement, prospectus supplement and prospectus. Any representation to the contrary
is a criminal offense.
Pricing supplement no
to product supplement no. 4-I dated April 15, 2016 and the prospectus and prospectus supplement, each dated April 15, 2016
Key
Terms
Issuer:
JPMorgan
Chase Financial Company LLC
Guarantor:
JPMorgan Chase & Co.
Reference
Stocks:
As specified under “Key Terms Relating to the Reference
Stocks” in this pricing supplement
Contingent Interest Payments:
If the notes have not been automatically called and the closing
price of one share of each Reference Stock on any Review Date is greater than or equal to its Interest Barrier, you will receive
on the applicable Interest Payment Date for each $1,000 principal amount note a Contingent Interest Payment equal to at least $31.875
(equivalent to a Contingent Interest Rate of at least 12.75% per annum, payable at a rate of at least 3.1875% per quarter) (to
be provided in the pricing supplement),
plus
any previously unpaid Contingent Interest Payments for any prior Review Dates.
If the Contingent Interest Payment is not paid on any Interest
Payment Date, that unpaid Contingent Interest Payment will be paid on a later Interest Payment Date if the closing price of one
share of each Reference Stock on the Review Date related to that later Interest Payment Date is greater than or equal to its Interest
Barrier. You will not receive any unpaid Contingent Interest Payments if the closing price of one share of any Reference Stock
on each subsequent Review Date is less than its Interest Barrier.
Contingent
Interest Rate:
At least 12.75% per annum, payable at a rate of at least
3.1875% per quarter (to be provided in the pricing supplement)
Interest Barrier
/ Trigger Value:
With respect to each Reference Stock, 65.00% of its
Initial Value, as specified under “Key Terms Relating to the Reference Stocks” in this pricing supplement
Pricing Date:
On or about May 13, 2016
Original Issue
Date (Settlement Date):
On or about May 20, 2016
Review Dates*:
August 15, 2016, November 14, 2016, February 13, 2017, May 15,
2017, August 14, 2017 and November 13, 2017 (final Review Date)
Interest Payment
Dates*:
August 22, 2016, November 21, 2016, February 21, 2017, May 22, 2017, August
21, 2017 and the Maturity Date
Maturity Date*:
November 20, 2017
Call Settlement
Date*:
If the notes are automatically called on any Review Date (other
than the first and final Review Dates), the first Interest Payment Date immediately following that Review Date
* Subject to postponement in the event of a market
disruption event and as described under “General Terms of Notes — Postponement of a Determination Date — Notes
Linked to Multiple Underlyings” and “General Terms of Notes — Postponement of a Payment Date” in the accompanying
product supplement
|
Automatic Call:
If the closing price of one
share of each Reference Stock on any Review Date (other than the first and final Review Dates) is greater than or equal to its
Initial Value, the notes will be automatically called for a cash payment, for each $1,000 principal amount note, equal to (a) $1,000
plus
(b) the Contingent Interest Payment applicable to that Review Date
plus
(c) any previously unpaid Contingent
Interest Payments for any prior Review Dates, payable on the applicable Call Settlement Date. No further payments will be made
on the notes.
Payment at Maturity:
If the notes have not been automatically called and the Final
Value of each Reference Stock is greater than or equal to its Trigger Value, you will receive a cash payment at maturity, for each
$1,000 principal amount note, equal to (a) $1,000
plus
(b) the Contingent Interest Payment applicable to the final Review
Date
plus
(c) any previously unpaid Contingent Interest Payments for any prior Review Dates.
If the notes have not been automatically called and the Final
Value of any Reference Stock is less than its Trigger Value, your payment at maturity per $1,000 principal amount note will be
calculated as follows:
$1,000 + ($1,000 × Least Performing
Stock Return)
If the notes have not been
automatically called and the Final Value of any Reference Stock is less than its Trigger Value, you will lose more than 35.00%
of your principal amount at maturity and could lose all of your principal amount at maturity.
Least Performing
Reference Stock:
The Reference Stock with the Least Performing Stock
Return
Least Performing
Stock Return:
The lowest of the Stock Returns of the Reference Stocks
Stock Return:
With respect to each Reference Stock,
(Final Value – Initial Value)
Initial Value
Initial Value:
With respect to each Reference Stock, the closing price of one share
of that Reference Stock on the Pricing Date, as specified under “Key Terms Relating to the Reference Stock” in this
pricing supplement
Final Value:
With respect to each Reference Stock, the closing price of one
share of that Reference Stock on the final Review Date
Stock Adjustment
Factor:
With respect to each Reference Stock, the Stock Adjustment
Factor is referenced in determining the closing price of one share of that Reference Stock and is set equal to 1.0 on the Pricing
Date. The Stock Adjustment Factor of each Reference Stock is subject to adjustment upon the occurrence of certain corporate events
affecting that Reference Stock. See “The Underlyings — Reference Stocks — Anti-Dilution Adjustments” and
“The Underlyings — Reference Stocks — Reorganization Events” in the accompanying product supplement for
further information.
|
PS-
1
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
Key
Terms Relating to the Reference Stocks
Reference Stock
|
Bloomberg Ticker Symbol
|
Initial Value
|
Interest Barrier / Trigger Value
|
American depositary shares (“ADSs”), each representing one ordinary share of Teva Pharmaceutical Industries Limited
|
TEVA
|
$
|
$
|
Common stock of Pfizer Inc., par value $0.05 per share
|
PFE
|
$
|
$
|
Common stock of Gilead Sciences, Inc., par value $0.001 per share
|
GILD
|
$
|
$
|
How
the Notes Work
Payments in Connection with the First Review
Date
PS-
2
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
Payments in Connection with Review Dates
(Other Than the First and Final Review Dates)
Payment at Maturity If the Notes Have Not
Been Automatically Called
Total Contingent Interest Payments
The table below illustrates the hypothetical total
Contingent Interest Payments per $1,000 principal amount note over the term of the notes based on a hypothetical Contingent Interest
Rate of 12.75% per annum, depending on how many Contingent Interest Payments are made prior to automatic call or maturity. The
actual Contingent Interest Rate will be provided in the pricing supplement and will be at least 12.75% per annum.
Number of Contingent Interest Payments
|
Total Contingent Interest Payments
|
6
|
$191.250
|
5
|
$159.375
|
4
|
$127.500
|
3
|
$95.625
|
2
|
$63.750
|
1
|
$31.875
|
0
|
$0.000
|
PS-
3
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
Hypothetical
Payout Examples
The following examples illustrate payments on
the notes linked to three hypothetical Reference Stocks, assuming a range of performances for the hypothetical Least Performing
Reference Stock on the Review Dates.
Each hypothetical payment set forth below assumes that the closing price of one share
of each Reference Stock that is not the Least Performing Reference Stock on each Review Date is greater than or equal to its Initial
Value (and therefore its Interest Barrier and Trigger Value).
In addition, the hypothetical payments set forth
below assume the following:
|
·
|
an Initial Value for the Least Performing Reference Stock of $100.00;
|
|
·
|
an Interest Barrier and a Trigger Value for the Least Performing Reference Stock of $65.00 (equal to 65.00% of its hypothetical
Initial Value); and
|
|
·
|
a Contingent Interest Rate of 12.75% per annum (payable at a rate of 3.1875% per quarter).
|
The hypothetical Initial Value of the Least Performing
Reference Stock of $100.00 has been chosen for illustrative purposes only and may not represent a likely actual Initial Value of
any Reference Stock. The actual Initial Value of each Reference Stock will be the closing price of one share of that Reference
Stock on the Pricing Date and will be provided in the pricing supplement. For historical data regarding the actual closing
prices of one share of each Reference Stock, please see the historical information set forth under “The Reference Stocks”
in this pricing supplement.
Each hypothetical payment set forth below is for
illustrative purposes only and may not be the actual payment applicable to a purchaser of the notes. The numbers appearing
in the following examples have been rounded for ease of analysis.
Example 1 — Notes
are automatically called on the second Review Date.
Date
|
Closing Price of One Share of the Least Performing Reference Stock
|
Payment (per $1,000 principal amount note)
|
First Review Date
|
$105.00
|
$31.875
|
Second Review Date
|
$105.00
|
$1,031.875
|
|
Total Payment
|
$1,063.75 (6.375% return)
|
Because the closing price of one share of each
Reference Stock on the Review Date is greater than or equal to its Initial Value, the notes will be automatically called for a
cash payment, for each $1,000 principal amount note, of $1,031.875 (or $1,000
plus
the Contingent Interest Payment applicable
to the Review Date), payable on the applicable Call Settlement Date. The notes are not automatically callable before the second
Review Date, even though the closing price of one share of each Reference Stock on the first Review Date is greater than its Initial
Value. When added to the Contingent Interest Payments received with respect to the prior Review Date, the total amount paid, for
each $1,000 principal amount note, is $1,063.75. No further payments will be made on the notes.
Example 2 — Notes have NOT been automatically
called and the Final Value of the Least Performing Reference Stock is greater than or equal to its Trigger Value.
Date
|
Closing Price of One Share of the Least Performing Reference Stock
|
Payment (per $1,000 principal amount note)
|
First Review Date
|
$95.00
|
$31.875
|
Second Review Date
|
$85.00
|
$31.875
|
Third through Fifth Review Dates
|
Less than Interest Barrier
|
$0
|
Final Review Date
|
$90.00
|
$1,127.50
|
|
Total Payment
|
$1,191.25 (19.125% return)
|
Because the notes have not been automatically
called and the Final Value of the Least Performing Reference Stock is greater than or equal to its Trigger Value, the payment at
maturity, for each $1,000 principal amount note, will be $1,127.50 (or $1,000
plus
the
PS-
4
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
Contingent Interest Payment applicable to the
final Review Date
plus
the unpaid Contingent Interest Payments for any prior Interest Review Dates). When added to the Contingent
Interest Payments received with respect to the prior Review Dates, the total amount paid, for each $1,000 principal amount note,
is $1,191.25.
Example 3 — Notes have NOT been automatically
called and the Final Value of the Least Performing Reference Stock is less than its Trigger Value.
Date
|
Closing Price of One Share of the Least Performing Reference Stock
|
Payment (per $1,000 principal amount note)
|
First Review Date
|
$60.00
|
$0
|
Second Review Date
|
$55.00
|
$0
|
Third through Fifth Review Dates
|
Less than Interest Barrier
|
$0
|
Final Review Date
|
$50.00
|
$500.00
|
|
Total Payment
|
$500.00 (-50.00% return)
|
Because the notes have not been automatically
called and the Final Value of the Least Performing Reference Stock is less than its Trigger Value and the Least Performing Stock
Return is -50.00%, the payment at maturity will be $500.00 per $1,000 principal amount note, calculated as follows:
$1,000 + [$1,000
×
(-50.00%)] = $500.00
The hypothetical returns and hypothetical payments
on the notes shown above apply
only if you hold the notes for their entire term or until automatically called.
These hypotheticals
do not reflect the fees or expenses that would be associated with any sale in the secondary market. If these fees and expenses
were included, the hypothetical returns and hypothetical payments shown above would likely be lower.
Selected
Risk Considerations
An investment in the notes involves significant
risks. These risks are explained in more detail in the “Risk Factors” section of the accompanying product supplement.
|
·
|
YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS —
|
The notes do not guarantee any return
of principal. If the notes have not been automatically called and the Final Value of any Reference Stock is less than its Trigger
Value, you will lose 1% of the principal amount of your notes for every 1% that the Final Value of the Least Performing Reference
Stock is less than its Initial Value. Accordingly, under these circumstances, you will lose more than 35.00% of your principal
amount at maturity and could lose all of your principal amount at maturity.
|
·
|
THE NOTES DO NOT GUARANTEE THE PAYMENT OF INTEREST AND MAY NOT PAY ANY INTEREST AT ALL —
|
If the notes have not been automatically
called, we will make a Contingent Interest Payment with respect to a Review Date (and we will pay you any previously unpaid Contingent
Interest Payments for any prior Review Dates) only if the closing price of one share of each Reference Stock on that Review Date
is greater than or equal to its Interest Barrier. If the closing price of one share of any Reference Stock on that Review Date
is less than its Interest Barrier, no Contingent Interest Payment will be made with respect to that Review Date.
You will not receive any unpaid Contingent
Interest Payments if the closing price of one share of the Reference Stock on each subsequent Review Date is less than the Interest
Barrier. Accordingly, if the closing price of one share of any Reference Stock on each Review Date is less than its Interest Barrier,
you will not receive any interest payments over the term of the notes.
|
·
|
CREDIT RISKS OF JPMORGAN FINANCIAL AND JPMORGAN CHASE & CO. —
|
Investors are dependent on our and
JPMorgan Chase & Co.’s ability to pay all amounts due on the notes. Any actual or potential change in our or JPMorgan
Chase & Co.’s creditworthiness or credit spreads, as determined by the market for taking that credit risk, is likely
to adversely affect the value of the notes. If we and JPMorgan Chase & Co. were to default on our payment obligations, you
may not receive any amounts owed to you under the notes and you could lose your entire investment.
PS-
5
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
|
·
|
AS A FINANCE SUBSIDIARY, JPMORGAN FINANCIAL HAS NO INDEPENDENT OPERATIONS AND HAS LIMITED ASSETS
|
As a finance subsidiary of JPMorgan
Chase & Co., we have no independent operations beyond the issuance and administration of our securities. Aside from the initial
capital contribution from JPMorgan Chase & Co., substantially all of our assets relate to obligations of our affiliates to
make payments under loans made by us or other intercompany agreements. As a result, we are dependent upon payments from our affiliates
to meet our obligations under the notes. If these affiliates do not make payments to us and we fail to make payments on the notes,
you may have to seek payment under the related guarantee by JPMorgan Chase & Co., and that guarantee will rank pari passu with
all other unsecured and unsubordinated obligations of JPMorgan Chase & Co.
|
·
|
THE APPRECIATION POTENTIAL OF THE NOTES IS LIMITED TO THE SUM OF ANY CONTINGENT INTEREST PAYMENTS
THAT MAY BE PAID OVER THE TERM OF THE NOTES,
|
regardless of any appreciation in the
price of any Reference Stock, which may be significant. You will not participate in any appreciation in the price of any Reference
Stock.
We and our affiliates play a variety
of roles in connection with the notes. In performing these duties, our and JPMorgan Chase & Co.’s economic interests
are potentially adverse to your interests as an investor in the notes. It is possible that hedging or trading activities of ours
or our affiliates in connection with the notes could result in substantial returns for us or our affiliates while the value of
the notes declines. Please refer to “Risk Factors — Risks Relating to Conflicts of Interest” in the accompanying
product supplement.
|
·
|
YOU ARE EXPOSED TO THE RISK OF DECLINE IN THE VALUE OF EACH REFERENCE STOCK —
|
Payments on the notes are not linked
to a basket composed of the Reference Stocks and are contingent upon the performance of each individual Reference Stock. Poor performance
by any of the Reference Stocks over the term of the notes may negatively affect whether you will receive a Contingent Interest
Payment on any Interest Payment Date and your payment at maturity and will not be offset or mitigated by positive performance by
any other Reference Stock.
|
·
|
YOUR PAYMENT AT MATURITY MAY BE DETERMINED BY THE LEAST PERFORMING REFERENCE STOCK.
|
|
·
|
THE BENEFIT PROVIDED BY THE TRIGGER VALUE MAY TERMINATE ON THE FINAL REVIEW DATE —
|
If the Final Value of any Reference
Stock is less than its Trigger Value and the notes have not been automatically called, the benefit provided by the Trigger Value
will terminate and you will be fully exposed to any depreciation in the closing price of one share of the Least Performing Reference
Stock.
|
·
|
THE AUTOMATIC CALL FEATURE MAY FORCE A POTENTIAL EARLY EXIT —
|
If your notes are automatically called,
the term of the notes may be reduced to as short as approximately six months and you will not receive any Contingent Interest Payments
after the applicable Call Settlement Date. There is no guarantee that you would be able to reinvest the proceeds from an investment
in the notes at a comparable return and/or with a comparable interest rate for a similar level of risk. Even in cases where the
notes are called before maturity, you are not entitled to any fees and commissions described on the front cover of this pricing
supplement.
|
·
|
YOU WILL NOT RECEIVE DIVIDENDS ON ANY REFERENCE STOCK OR HAVE ANY RIGHTS WITH RESPECT TO ANY REFERENCE
STOCK.
|
|
·
|
NO AFFILIATION WITH ANY REFERENCE STOCK ISSUER —
|
We have not independently verified
any of the information about any Reference Stock issuer contained in this pricing supplement. You should undertake your own investigation
into each Reference Stock and its issuer. We are not responsible for any Reference Stock issuer’s public disclosure of information,
whether contained in SEC filings or otherwise.
|
·
|
RISKS ASSOCIATED WITH NON-U.S. COMPANIES WITH RESPECT TO THE ADSs OF TEVA PHARMACEUTICAL INDUSTRIES
LIMITED —
|
The ADSs of Teva Pharmaceutical Industries
Limited have been issued by a non-U.S. company. Investments in securities linked to the value of such non-U.S. equity securities
involve risks associated with the securities markets in the home countries of the issuers of those non-U.S. equity securities.
PS-
6
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
|
·
|
THE NOTES ARE SUBJECT TO CURRENCY EXCHANGE RATE RISK WITH RESPECT TO THE ADSs OF TEVA PHARMACEUTICAL
INDUSTRIES LIMITED —
|
Because the ADSs of Teva Pharmaceutical
Industries Limited is quoted and traded in U.S. dollars on the New York Stock Exchange and the ordinary shares of Teva Pharmaceutical
Industries Limited, which we refer to as the underlying stock, are traded and quoted in new Israeli shekel on the Tel Aviv Stock
Exchange, holders of the notes will be exposed to currency exchange rate risk with respect to the new Israeli shekel. If
the U.S. dollar strengthens against the new Israeli shekel, the price of the ADSs of Teva Pharmaceutical Industries Limited will
be adversely affected and any payment on the notes may be reduced.
|
·
|
THERE ARE IMPORTANT DIFFERENCES BETWEEN THE RIGHTS OF HOLDERS OF THE ADSs OF TEVA PHARMACEUTICAL
INDUSTRIES LIMITED AND THE RIGHTS OF HOLDERS OF THE UNDERLYING STOCK —
|
There are important differences between
the rights of holders of the ADSs of Teva Pharmaceutical Industries Limited and the rights of holders of the underlying stock.
For example, the issuer of the underlying stock may make distributions in respect of the underlying stock that are not passed on
to the holders of the ADSs of Teva Pharmaceutical Industries Limited. Any such differences between the rights of holders
of the underlying stock may be significant and may materially and adversely affect the value of the ADSs of Teva Pharmaceutical
Industries Limited and, as a result, the notes.
|
·
|
THE ANTI-DILUTION PROTECTION FOR THE REFERENCE STOCKS IS LIMITED AND MAY BE DISCRETIONARY —
|
The calculation agent will not make
an adjustment in response to all events that could affect a Reference Stock. The calculation agent may make adjustments in response
to events that are not described in the accompanying product supplement to account for any diluting or concentrative effect, but
the calculation agent is under no obligation to do so or to consider your interests as a holder of the notes in making these determinations.
|
·
|
THE RISK OF THE CLOSING PRICE OF A REFERENCE STOCK FALLING BELOW ITS INTEREST BARRIER OR TRIGGER
VALUE IS GREATER IF THE PRICE OF THAT REFERENCE STOCK IS VOLATILE.
|
The notes will not be listed on any
securities exchange. Accordingly, the price at which you may be able to trade your notes is likely to depend on the price, if any,
at which JPMS is willing to buy the notes. You may not be able to sell your notes. The notes are not designed to be short-term
trading instruments. Accordingly, you should be able and willing to hold your notes to maturity.
|
·
|
THE FINAL TERMS AND VALUATION OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT —
|
You should consider your potential
investment in the notes based on the minimums for the estimated value of the notes and the Contingent Interest Rate.
|
·
|
THE ESTIMATED VALUE OF THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC)
OF THE NOTES —
|
The estimated value of the notes is
only an estimate determined by reference to several factors. The original issue price of the notes will exceed the estimated value
of the notes because costs associated with selling, structuring and hedging the notes are included in the original issue price
of the notes. These costs include the selling commissions, the projected profits, if any, that our affiliates expect to realize
for assuming risks inherent in hedging our obligations under the notes and the estimated cost of hedging our obligations under
the notes. See “The Estimated Value of the Notes” in this pricing supplement.
|
·
|
THE ESTIMATED VALUE OF THE NOTES DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER
FROM OTHERS’ ESTIMATES —
|
See “The Estimated Value of the
Notes” in this pricing supplement.
|
·
|
THE ESTIMATED VALUE OF THE NOTES IS DERIVED BY REFERENCE TO AN INTERNAL FUNDING RATE —
|
The internal funding rate used in the
determination of the estimated value of the notes is based on, among other things, our and our affiliates’ view of the funding
value of the notes as well as the higher issuance, operational and ongoing liability management costs of the notes in comparison
to those costs for the conventional fixed-rate debt of JPMorgan Chase & Co. The use of an internal funding rate and any potential
changes to that rate may have an adverse effect on the terms of the notes and any secondary market prices of the notes. See “The
Estimated Value of the Notes” in this pricing supplement.
PS-
7
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
|
·
|
THE VALUE OF THE NOTES AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT STATEMENTS)
MAY BE HIGHER THAN THE THEN-CURRENT ESTIMATED VALUE OF THE NOTES FOR A LIMITED TIME PERIOD —
|
We generally expect that some of the
costs included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of
your notes by JPMS in an amount that will decline to zero over an initial predetermined period. See “Secondary Market Prices
of the Notes” in this pricing supplement for additional information relating to this initial period. Accordingly, the estimated
value of your notes during this initial period may be lower than the value of the notes as published by JPMS (and which may be
shown on your customer account statements).
|
·
|
SECONDARY MARKET PRICES OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE
NOTES —
|
Any secondary market prices of the
notes will likely be lower than the original issue price of the notes because, among other things, secondary market prices take
into account our internal secondary market funding rates for structured debt issuances and, also, because secondary market prices
(a) exclude selling commissions and (b) may exclude projected hedging profits, if any, and estimated hedging costs that are included
in the original issue price of the notes. As a result, the price, if any, at which JPMS will be willing to buy the notes from you
in secondary market transactions, if at all, is likely to be lower than the original issue price. Any sale by you prior to the
Maturity Date could result in a substantial loss to you.
|
·
|
SECONDARY MARKET PRICES OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS —
|
The secondary market price of the notes
during their term will be impacted by a number of economic and market factors, which may either offset or magnify each other, aside
from the selling commissions, projected hedging profits, if any, estimated hedging costs and the prices of the Reference Stocks.
Additionally, independent pricing vendors and/or third party broker-dealers may publish a price for the notes, which may also be
reflected on customer account statements. This price may be different (higher or lower) than the price of the notes, if any, at
which JPMS may be willing to purchase your notes in the secondary market. See “Risk Factors — Risks Relating to the
Estimated Value and Secondary Market Prices of the Notes — Secondary market prices of the notes will be impacted by many
economic and market factors” in the accompanying product supplement.
PS-
8
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
The Reference Stocks
All information contained herein on the Reference
Stocks and on the Reference Stock issuers is derived from publicly available sources, without independent verification. Each Reference
Stock is registered under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act, and is listed
on the exchange provided in the table below, which we refer to as the relevant exchange for purposes of that Reference Stock in
the accompanying product supplement. Information provided to or filed with the SEC by a Reference Stock issuer pursuant to the
Exchange Act can be located by reference to the SEC file number provided in the table below, and can be accessed through www.sec.gov.
We do not make any representation that these publicly available documents are accurate or complete. We obtained the closing prices
below from the Bloomberg Professional
®
service (“Bloomberg”) without independent verification.
Reference Stock
|
Bloomberg Ticker Symbol
|
Relevant Exchange
|
SEC File Number
|
Closing Price on April 28, 2016
|
ADSs, each representing one ordinary share, of Teva Pharmaceutical Industries Limited
|
TEVA
|
New York Stock Exchange
|
001-16174
|
$54.99
|
Common stock of Pfizer Inc., par value $0.05 per share
|
PFE
|
New York Stock Exchange
|
001-03619
|
$32.91
|
Common stock of Gilead Sciences, Inc., par value $0.001 per share
|
GILD
|
The NASDAQ Stock Market
|
000-19731
|
$97.00
|
Each of the Reference Stocks is issued by a company
whose primary line of business is associated with the pharmaceutical industry.
According to publicly available filings of the
relevant Reference Stock issuer with the SEC:
|
·
|
Teva Pharmaceutical Industries Limited, an Israeli company, is a global pharmaceutical
company that develops, produces and markets generic medicines and a portfolio of specialty medicines.
|
|
·
|
Pfizer Inc. is a research-based, global biopharmaceutical company. Pfizer
Inc.’s global portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products.
|
|
·
|
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes medicines in areas of unmet medical need. Gilead’s primary areas of focus include
human immunodeficiency virus, liver diseases such as chronic hepatitis C virus infection and chronic hepatitis B virus infection,
cardiovascular, hematology/oncology and inflammation/ respiratory.
|
Historical Information
The following graphs set forth the historical
performances of the Reference Stocks based on the weekly historical closing prices of one share of each Reference Stock from January
7, 2011 through April 22, 2016. The closing prices above and below may have been adjusted by Bloomberg for corporate actions, such
as stock splits, public offerings, mergers and acquisitions, spin-offs, delistings and bankruptcy.
The historical closing prices of one share of
each Reference Stock should not be taken as an indication of future performance, and no assurance can be given as to the closing
price of one share of any Reference Stock on the Pricing Date or any Review Date. There can be no assurance that the performance
of the Reference Stocks will result in the return of any of your principal amount or the payment of any interest.
PS-
9
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
PS-
10
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
Tax
Treatment
You should review carefully the section entitled
“Material U.S. Federal Income Tax Consequences” in the accompanying product supplement no. 4-I. In determining our
reporting responsibilities we intend to treat (i) the notes for U.S. federal income tax purposes as prepaid forward contracts with
associated contingent coupons and (ii) any Contingent Interest Payments as ordinary income, as described in the section entitled
“Material U.S. Federal Income Tax Consequences — Tax Consequences to U.S. Holders — Notes Treated as Prepaid
Forward Contracts with Associated Contingent Coupons” in the accompanying product supplement. Based on the advice of Davis
Polk & Wardwell LLP, our special tax counsel, we believe that this is a reasonable treatment, but that there are other reasonable
treatments that the IRS or a court may adopt, in which case the timing and character of any income or loss on the notes could be
materially affected. In addition, in 2007 Treasury and the IRS released a notice requesting comments on the U.S. federal income
tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses in particular on whether to
require investors in these instruments to accrue income over the term of their investment. It also asks for comments on a number
of related topics, including the character of income or loss with respect to these instruments and the relevance of factors such
as the nature of the underlying property to which the instruments are linked. While the notice requests comments on appropriate
transition rules and effective dates, any Treasury regulations or other guidance promulgated after consideration of these issues
could materially affect the tax consequences of an investment in the notes, possibly with retroactive effect. You should consult
your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes, including possible alternative
treatments and the issues presented by this notice.
Non-U.S. Holders — Tax Considerations
.
The U.S. federal income tax treatment of Contingent Interest Payments is uncertain, and although we believe it is reasonable to
take a position that Contingent Interest Payments are not subject to U.S. withholding tax (at least if an applicable Form W-8 is
provided), a withholding agent may nonetheless withhold on these payments (generally at a rate of 30%, subject to the possible
reduction of that rate under an applicable income tax treaty), unless income from your notes is effectively connected with your
conduct of a trade or business in the United States (and, if an applicable treaty so requires, attributable to a permanent establishment
in the United States). If you are not a United States person, you are urged to consult your tax adviser regarding the U.S. federal
income tax consequences of an investment in the notes in light of your particular circumstances.
Non-U.S. holders should also note that, notwithstanding
anything to the contrary in the accompanying product supplement, recently promulgated Treasury regulations imposing a withholding
tax on certain “dividend equivalents” under certain “equity linked instruments” will not apply to the notes.
FATCA.
Withholding under legislation
commonly referred to as “FATCA” could apply to payments with respect to the notes that are treated as U.S.-source “fixed
or determinable annual or periodical” income (“FDAP Income”) for U.S. federal income tax purposes (such as interest,
if the notes are recharacterized, in whole or in part, as debt instruments, or Contingent Interest Payments if they are otherwise
treated as FDAP Income). Notwithstanding anything to the contrary in the accompanying product supplement, under a recent IRS notice,
withholding under FATCA will not apply to payments of gross proceeds (other than any amount treated as FDAP Income) of a taxable
disposition, including an early redemption or redemption at maturity, of the notes. You should consult your tax adviser regarding
the potential application of FATCA to the notes.
In the event of any withholding on the notes,
we will not be required to pay any additional amounts with respect to amounts so withheld.
The
Estimated Value of the Notes
The estimated value of the notes set forth
on the cover of this pricing supplement is equal to the sum of the values of the following hypothetical components: (1) a fixed-income
debt component with the same maturity as the notes, valued using the internal funding rate described below, and (2) the derivative
or derivatives underlying the economic terms of the notes. The estimated value of the notes does not represent a minimum price
at which JPMS would be willing to buy your notes in any secondary market (if any exists) at any time. The internal funding rate
used in the determination of the estimated value of the notes is based on, among other things, our and our affiliates’ view
of the funding value of the notes as well as the higher issuance, operational and ongoing liability management costs of the notes
in comparison to those costs for the conventional fixed-rate debt of JPMorgan Chase & Co. For additional information, see “Selected
Risk Considerations — The Estimated Value of the Notes Is Derived by Reference to an Internal Funding Rate” in this
pricing supplement.
The value of the derivative or derivatives
underlying the economic terms of the notes is derived from internal pricing models of our affiliates. These models are dependent
on inputs such as the traded market prices of comparable derivative instruments and on various other inputs, some of which are
market-observable, and which can include volatility, dividend rates, interest rates and other factors, as well as assumptions about
future market events and/or environments. Accordingly, the estimated value of the notes is
PS-
11
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
determined when the terms of the notes are
set based on market conditions and other relevant factors and assumptions existing at that time.
The estimated value of the notes does not
represent future values of the notes and may differ from others’ estimates. Different pricing models and assumptions could
provide valuations for the notes that are greater than or less than the estimated value of the notes. In addition, market conditions
and other relevant factors in the future may change, and any assumptions may prove to be incorrect. On future dates, the value
of the notes could change significantly based on, among other things, changes in market conditions, our or JPMorgan Chase &
Co.’s creditworthiness, interest rate movements and other relevant factors, which may impact the price, if any, at which
JPMS would be willing to buy notes from you in secondary market transactions.
The estimated value of the notes will be
lower than the original issue price of the notes because costs associated with selling, structuring and hedging the notes are included
in the original issue price of the notes. These costs include the selling commissions paid to JPMS and other affiliated or unaffiliated
dealers, the projected profits, if any, that our affiliates expect to realize for assuming risks inherent in hedging our obligations
under the notes and the estimated cost of hedging our obligations under the notes. Because hedging our obligations entails risk
and may be influenced by market forces beyond our control, this hedging may result in a profit that is more or less than expected,
or it may result in a loss. A portion of the profits, if any, realized in hedging our obligations under the notes may be allowed
to other affiliated or unaffiliated dealers, and we or one or more of our affiliates will retain any remaining hedging profits.
See “Selected Risk Considerations — The Estimated Value and the Notes Will Be Lower Than the Original Issue Price (Price
to Public) of the Notes” in this pricing supplement.
Secondary
Market Prices of the Notes
For information about factors that will impact
any secondary market prices of the notes, see “Risk Factors — Risks Relating to the Estimated Value and Secondary Market
Prices of the Notes — Secondary market prices of the notes will be impacted by many economic and market factors” in
the accompanying product supplement. In addition, we generally expect that some of the costs included in the original issue price
of the notes will be partially paid back to you in connection with any repurchases of your notes by JPMS in an amount that will
decline to zero over an initial predetermined period. These costs can include projected hedging profits, if any, and, in some circumstances,
estimated hedging costs and our internal secondary market funding rates for structured debt issuances. This initial predetermined
time period is intended to be the shorter of six months and one-half of the stated term of the notes. The length of any such initial
period reflects the structure of the notes, whether our affiliates expect to earn a profit in connection with our hedging activities,
the estimated costs of hedging the notes and when these costs are incurred, as determined by our affiliates. See “Selected
Risk Considerations — The Value of the Notes as Published by JPMS (and Which May Be Reflected on Customer Account Statements)
May Be Higher Than the Then-Current Estimated Value of the Notes for a Limited Time Period” in this pricing supplement.
Supplemental
Use of Proceeds
The notes are offered to meet investor demand
for products that reflect the risk-return profile and market exposure provided by the notes. See “How the Notes Work”
and “Hypothetical Payout Examples” in this pricing supplement for an illustration of the risk-return profile of the
notes and “The Reference Stocks” in this pricing supplement for a description of the market exposure provided by the
notes.
The original issue price of the notes is
equal to the estimated value of the notes plus the selling commissions paid to JPMS and other affiliated or unaffiliated dealers,
plus (minus) the projected profits (losses) that our affiliates expect to realize for assuming risks inherent in hedging our obligations
under the notes, plus the estimated cost of hedging our obligations under the notes.
Supplemental
Plan of Distribution
We expect that delivery of the notes will be made
against payment for the notes on or about the Original Issue Date set forth on the front cover of this pricing supplement, which
will be the fifth business day following the expected Pricing Date of the notes (this settlement cycle being referred to as T+5).
Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required
to settle in three business days, unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish
to trade notes on the Pricing Date or the succeeding business day will be required to specify an alternate settlement cycle at
the time of any such trade to prevent a failed settlement and should consult their own advisors.
PS-
12
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
Additional
Terms Specific to the Notes
You may revoke your offer to purchase the notes
at any time prior to the time at which we accept such offer by notifying the applicable agent. We reserve the right to change the
terms of, or reject any offer to purchase, the notes prior to their issuance. In the event of any changes to the terms of the notes,
we will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject
such changes, in which case we may reject your offer to purchase.
You should read this pricing supplement together
with the accompanying prospectus, as supplemented by the accompanying prospectus supplement, relating to our Series A medium-term
notes of which these notes are a part, and the more detailed information contained in the accompanying product supplement. This
pricing supplement, together with the documents listed below, contains the terms of the notes and supersedes all other prior or
contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence,
trade ideas, structures for implementation, sample structures, fact sheets, brochures or other educational materials of ours. You
should carefully consider, among other things, the matters set forth in the “Risk Factors” sections of the accompanying
product supplement, as the notes involve risks not associated with conventional debt securities. We urge you to consult your investment,
legal, tax, accounting and other advisers before you invest in the notes.
You may access these documents on the SEC
website at www.sec.gov as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):
Our
Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing
supplement, “we,” “us” and “our” refer to JPMorgan Financial.
PS-
13
| Structured Investments
Auto Callable Contingent Interest Notes Linked to the Least Performing of the American Depositary Shares of Teva Pharmaceutical Industries Limited, the Common Stock of Pfizer Inc. and the Common Stock of Gilead Sciences, Inc.
|
|
JP Morgan Chase (NYSE:JPM)
Historical Stock Chart
From Mar 2024 to Apr 2024
JP Morgan Chase (NYSE:JPM)
Historical Stock Chart
From Apr 2023 to Apr 2024